Plasma fractionation technology is essential for manufacturing plasma-derived medicines used in critical care and chronic disease management. It supports modern transfusion and immunotherapy practices.

Plasma Fractionation Market In-depth Analysis and Overview

The Plasma Fractionation Market is projected to grow from US$ 26,575.83 million in 2021 to US$ 40,731.98 million by 2028, registering a CAGR of 6.3% during 2021 to 2028. Plasma fractionation is the process of separating plasma into its individual protein components to develop therapeutic products such as immunoglobulins, albumin, coagulation factor concentrates, and protease inhibitors. These plasma derived therapies play a vital role in treating immune deficiencies, hemophilia, neurological disorders, and critical care conditions.

Market growth is largely driven by the increasing application of plasma therapy for chronic and infectious diseases. Rising awareness about plasma derived products and improvements in healthcare infrastructure across developed and developing countries are contributing to steady expansion. The COVID 19 pandemic also highlighted the importance of plasma therapies, further strengthening market demand.

Market Drivers

One of the major drivers of the Plasma Fractionation Market is the rising use of plasma therapy in the treatment of autoimmune diseases, infectious diseases, and hematological disorders. Regulatory support has encouraged broader application of plasma based treatments. For example, emergency use authorizations for convalescent plasma during the pandemic increased global awareness and investment in plasma collection and processing.

The increasing prevalence of neurological and immunological disorders is also fueling demand. Plasma components such as immunoglobulins are widely used in neurology and immunology applications. Growing healthcare investments and expansion of blood bank networks worldwide have improved plasma collection capabilities. In countries such as India, thousands of blood banks collect millions of blood units annually, though per capita usage of plasma derivatives remains lower compared to developed nations. This gap presents future growth opportunities.

Get a Free Sample PDF Here- https://www.theinsightpartners.com/sample/TIPRE00003422 

Segment Analysis

By product, the market is segmented into immunoglobulin, albumin, coagulation factor concentrates, protease inhibitors, and other plasma products. The immunoglobulin segment holds the largest market share and is expected to register the highest CAGR during the forecast period. Its dominance is attributed to increasing cases of infectious diseases and strong regulatory support for new product approvals. Immunoglobulins are further categorized into intravenous and subcutaneous formulations.

Based on application, the market is divided into neurology, immunology, hematology, critical care, pulmonology, and other applications. Neurology accounted for the largest share in 2021 due to rising cases of neurological disorders. However, hematology is expected to witness the fastest growth owing to improved detection and diagnosis of blood related conditions such as hemophilia.

By end user, the market includes hospitals and clinics, clinical research laboratories, and academic institutes. Hospitals and clinics represent the largest share due to high patient inflow and advanced treatment facilities. Clinical research laboratories are projected to grow at a significant pace as research activities increase globally.

Regional Insights

North America holds the largest share of the Plasma Fractionation Market, valued at US$ 9,484.91 million in 2021. The region benefits from advanced healthcare infrastructure, strong regulatory frameworks, and widespread adoption of plasma derived therapies. The United States, Canada, and Mexico are key contributors to regional growth.

Europe follows with steady demand for plasma products driven by increasing awareness and supportive healthcare policies. Asia Pacific is expected to grow at the fastest CAGR during the forecast period. Growth in China and India is supported by expanding healthcare infrastructure, government initiatives, and increasing participation of international players. The Middle East and Africa and South and Central America are gradually emerging as promising markets due to rising healthcare investments.

Key Market Players

Major companies operating in the Plasma Fractionation Market include:

• Bio Products Laboratory LTD
• CSL Limited
• Biotest AG
• Sanquin
• Bharat Serums and Vaccines Limited
• Grifols S.A
• Kedrion
• SK Plasma
• Plasmagen Biosciences Pvt. Ltd
• Octapharma AG

These companies are focusing on strategic collaborations, product launches, mergers, acquisitions, and research partnerships to strengthen their market presence. Leading players such as CSL Limited and Grifols S.A continue to invest heavily in plasma collection networks and advanced fractionation technologies.

Future Outlook

The future outlook of the Plasma Fractionation Market remains positive with sustained demand for plasma derived therapeutics. Increasing prevalence of chronic diseases, expanding plasma collection infrastructure, and advancements in fractionation technology will continue to drive market growth. Emerging economies are expected to play a critical role in the next phase of expansion as awareness and healthcare access improve. Continuous innovation, regulatory support, and strategic industry partnerships will further enhance market stability and long term growth prospects.

Related Reports:

Asia Pacific Plasma Fractionation Market

Albumin Market